Transient protein expression methods

Details Transient protein expression methods Transient protein expression methods

2007-06-01

2009-10-20

Chen, Stacy B (Department: 1648)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S320100, C435S455000, C424S233100

Reexamination Certificate

active

07604960

ABSTRACT:
Described is a method for producing a protein of interest, the method comprising: a) providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein the adenoviral vector has deletions in a first region and in a second region of the adenovirus genome, wherein each of the first region and the second region is required for adenoviral genome replication and/or adenovirus particle formation, b) propagating the adenoviral vector in a first type of complementing cells that express proteins from the first and from the second region of the adenovirus genome so as to complement the deletions of the recombinant adenoviral vector, to obtain recombinant adenovirus particles, c) infecting a culture of a second type of complementing cells with the recombinant adenovirus particles, wherein the second type of complementing cells express protein from the first region of the adenovirus genome but not protein from the second region of the adenovirus genome, to produce the protein of interest, and d) harvesting the protein of interest.

REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 4835260 (1989-05-01), Shoemaker
patent: 5047335 (1991-09-01), Paulson et al.
patent: 5192539 (1993-03-01), Van Der Marel et al.
patent: 5441868 (1995-08-01), Lin
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5494790 (1996-02-01), Sasaki et al.
patent: 5631158 (1997-05-01), Dorai et al.
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5789247 (1998-08-01), Ballay et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5835382 (1998-11-01), Wilson et al.
patent: 5856298 (1999-01-01), Strickland
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6037453 (2000-03-01), Jardieu et al.
patent: 6475753 (2002-11-01), Ruben et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6558948 (2003-05-01), Kochanek et al.
patent: 6653101 (2003-11-01), Cockett et al.
patent: 6855544 (2005-02-01), Hateboer et al.
patent: 6878549 (2005-04-01), Vogels et al.
patent: 2002/0116723 (2002-08-01), Grigliatti et al.
patent: 2003/0087437 (2003-05-01), Asada et al.
patent: 2003/0092160 (2003-05-01), Bout et al.
patent: 0 185 573 (1986-06-01), None
patent: 0 411 678 (1991-02-01), None
patent: 0 833 934 (1998-04-01), None
patent: WO 93/03163 (1993-02-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 95/29994 (1995-11-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 98/18926 (1998-05-01), None
patent: WO 98/39411 (1998-09-01), None
patent: WO 98/44141 (1998-10-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/24068 (1999-05-01), None
patent: WO 00/61164 (2000-10-01), None
patent: WO 00/63403 (2000-10-01), None
patent: WO 01/38362 (2001-05-01), None
patent: WO 02/053580 (2002-07-01), None
patent: WO 03/038100 (2003-05-01), None
patent: WO 03/048197 (2003-06-01), None
patent: WO 03/048348 (2003-06-01), None
patent: WO 03/051927 (2003-06-01), None
patent: WO 2004/003176 (2004-01-01), None
patent: WO 2004/099396 (2004-11-01), None
patent: WO 2007/134325 (2007-11-01), None
Zhou et al. Journal of Virology, 1996, 70(10):7030-7038.
#Alkhatib et al., “Expression of Bicistronic Measles Virus P/C mRNA by Using Hybrid Adenovirus: Levels of C Protein Synthesized In Vivo Are Unaffected by the Presence or Absence of the Upstream P Initiator Codon,” Journal of Virology, Nov. 1988, pp. 4059-4068, vol. 62, No. 11.
#Alkhatib et al., “High-Level Eurcaryotic In Vivo Expression of Biologically Active Measles Virus Hemagglutinin by Using an Adenovirus Type 5 Helper-Free Vector System,” Journal of Virology, Aug. 1988, pp. 2718-2727, vol. 62, No. 8.
#Berg et al., High-Level Expression of Secreted Proteins from Cells Adapted to Serum-Free Suspension Culture, Research Report, 1993, pp. 972-978, vol. 14, No. 6.
#Bout et al., “Improved helper cells for RCA-free production of E1-deleted recombinant adenovirus vectors,” Cancer Gene Therapy, 1996, pp. S24, vol. 3, No. 6.
#Bout et al., “Production of RCA-free batches of E1-deleted recombinant adenoviral vectors on PER.C6,” Nucleic Acids Symp. Ser. 1998, XP-002115716, pp. 35-36.
#Boutl et al., A novel packaging cell line (PER.C6) for efficient production of RCA-free batches of E1-deleted recombinant adenoviral vectors, Cancer Gene Therapy, 1997, pp. S32-S33, vol. 4, No. 6.
#Brown et al., “Evaluation of Cell Line 293 for Virus isolation in Routine Viral Diagnosis,” Journal of Clinical Microbiology, Apr. 1986, pp. 704-708, vol. 23, No. 4.
#Bukreyev et al., “Recombinant Respiratory Syncytial Virus from Which the Entire SH Gene Has Been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,” Journal of Virology, Dec. 1997, pp. 8973-8982, vol. 71, No. 12.
#Caravokri et al., “Constitutive Episomal Expression of Polypeptide l X (pIX) in a 293-Based Cell Line Complements that Deficiency of pIX Mutant Adenovirus Type 5,” Journal of Virology, Nov. 1995, pp. 6627-6633, vol. 69, No. 11.
#Carroll et al., Abstract, Differential Infection of Receptor-modified Host Cells by Receptor-Specific Influenza Viruses, Virus Research, Sep. 1985, pp. 165-179, vol. 3, No. 2.
#Ciccarone et al., “Lipofectamine 2000 Reagent for Transfection of Eukaryotic Cells,” Focus, 1999, pp. 54-55, vol. 21, No. 2.
#Cote et al., Serum-Free Production of Recombinant Proteins and Adenoviral Vectors by 293SF-3F6 Cells, Biotechnology and Bioengineering, Sep. 5, 1998, pp. 567-575, vol. 59, No. 5.
#Cronan, Abstract, Biotination of Proteins in-vivo a post-translational modification to label purify and study proteins, Journal of Biological Chemistry, Jun. 25, 1990, pp. 10327-10333, vol. 265, No. 18.
#DuBridge et al., “Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System,” Molecular and Cellular Biology, Jan. 1987, pp. 397-387, vol. 7, No. 1.
#Endo et al., Growth of Influenza A Virus in Primary, Differentiated Epithelial Cells Derived from Adenoids, Journal of Virology, Mar. 1996, pp. 2055-2058, vol. 70, No. 3.
#European Search Report 05 10 0732, Apr. 7, 2005.
#Fallaux et al, “New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses,” Human Gene Therapy, Sep. 1, 1998, vol. 9, No. 1, pp. 1909-1917. Abstract.
#Fallaux et al., Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors, Human Gene Therapy, Jan. 20, 1996, pp. 215-222, vol. 7.
#Gallimore et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, 1986, pp. 499-508, vol. 6.
#Garnier et al. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells, Cytotechnology, 1994, pp. 145-155, vol. 15.
#GenBank Accession No. X02996.1, 1993, “Adenovirus type 5 left 32% of the genome.”
#Ghosh-Choudhury et al., Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of the full length genomes, The EMBO Journal, 1987, pp. 1733-1739, vol. 6, No. 6.
#Grabenhorst et al., Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(beta-1-4)G1cNAc-R alpha-2,6-sialyltransferase alpha-2,6-Linked NeuAc is preferentially attached to the Gal(beta-1- 4)G1cNAc(beta-1-2)Man(alpha-1-3)-branch of diantennary oligosaccharides from secreted recombinant beta-trace protein, Eur. J. Biochem, 1995, pp. 718-725, vol. 232, No. 3, Berlin, Germany.
#Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen. Virol., 1977, pp. 59-72, vol. 36.
#Graham et al., “Growth of 293 cells in suspension culture,” J Gen Virol, Mar. 1987, pp. 937-940, vol. 68.
#Graham, Cell Lines, Promochem (visited Apr. 10, 2005) <http:

Affiliated with

Also associated with

Rating

Transient protein expression methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transient protein expression methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transient protein expression methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4095479